alexa First Case Report of Cutaneous Leishmaniasis Caused by Leishmania (Leishmania) infantum in a Brazilian Patient Treated with Adalimumab | Open Access Journals
ISSN: 2155-9554
Journal of Clinical & Experimental Dermatology Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

First Case Report of Cutaneous Leishmaniasis Caused by Leishmania (Leishmania) infantum in a Brazilian Patient Treated with Adalimumab

Thaíssa Araújo Aquino1, Sofia Sales Martins1, Ciro Martins Gomes1,2, Jorgeth de Oliveira Carneiro da Motta1,3, Daniel Graziani3, Amanda da Mota Silveira Rodrigues4, Rayane Marques Cardoso4, Beatriz Dolabela de Lima5 and Raimunda Nonata Ribeiro Sampaio1-3*
1Hospital University of Brasilia, University of Brasilia, Brasilia, DF, Brazil
2POS graduate of Medical Sciences, Laboratory of Dermatology, Faculty of Medicine, University of Brasília, Brasília, DF, Brazil
3POS graduate of the Faculty of Sciences, University of Brasília, Brasília Health, DF, Brazil
4Faculty of Medicine, University of Brasília, Brasília, DF, Brazil
5Laboratory of Gene Biology, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília, DF, Brazil
Corresponding Author : Raimunda Nonata Ribeiro Sampaio
Faculty of Medicine, University of Brasília
SHIS QI 25 Conj 2, Casa 1, Lago Sul, Brasília, DF, Brazil
Tel: +55618121 6100
E-mail: [email protected]
Received August 22, 2014; Accepted October 14, 2014; Published October 21, 2014
Citation: Aquino TA, Martins SS, Gomes CM, Carneiro da Motta JO, Graziani D, et al. (2014) First Case Report of Cutaneous Leishmaniasis Caused by Leishmania (Leishmania) infantum in a Brazilian Patient Treated with Adalimumab. J Clin Exp Dermatol Res 5:245. doi:10.4172/2155-9554.1000245
Copyright: © 2014 Thaíssa Araújo Aquino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Clinical & Experimental Dermatology Research

Abstract

Leishmania (Leishmania) infantum is the main etiologic agent of visceral leishmaniasis in American continent. We report a rare case of cutaneous leishmaniasis caused by viscerotropic specie in a patient with ankylosing spondylitis on treatment with adalimumabe and methotrexate. The patient presented no signs of visceral involvement. PCRRFLP and genetic sequencing demonstrated Leishmania (Leishmania) infantum. The patient was treated with Nmethyl- glucamine (20 mgSbV/kg/day) for 20 days. Despite of interruption of treatment due to elevation of transaminases (TGO 48 U/L and TGP 62 U/L) for a week, the lesions healed completely. Leishmania infection in patients who are on anti-TNF alpha treatment has to be remembered as an opportunistic disease associated with immunosuppression caused by biological therapies, especially in endemic countries. We consider that the use of immunosuppressive drugs may lead to atypical cases of cutaneous leishmaniasis even by viscerotropic agents.

Abstract
Leishmania (Leishmania) infantum is the main etiologic agent of visceral leishmaniasis in American continent. We report a rare case of cutaneous leishmaniasis caused by viscerotropic specie in a patient with ankylosing spondylitis on treatment with adalimumabe and methotrexate. The patient presented no signs of visceral involvement. PCR-RFLP and genetic sequencing demonstrated Leishmania (Leishmania) infantum. The patient was treated with N-methyl-glucamine (20 mgSbV/kg/day) for 20 days. Despite of interruption of treatment due to elevation of transaminases (TGO 48 U/L and TGP 62 U/L) for a week, the lesions healed completely
Leishmania infection in patients who are on anti-TNF alpha treatment has to be remembered as an opportunistic disease associated with immunosuppression caused by biological therapies, especially in endemic countries. We consider that the use of immunosuppressive drugs may lead to atypical cases of cutaneous leishmaniasis even by viscerotropic agents.
Keywords
Cutaneous leishmaniasis; Mucocutaneous leishmaniasis; Leishmania (Leishmania) infantum; Immunosuppressive agents; Tumor necrosis factor-alpha
Case Report
A 38-year-old male patient from Minas Gerais, Brazil, suffering from ankylosing spondylitis and psoriasis who was been treated with methotrexate (15 mg per week) and adalimumab (40 mg every other week) developed three ulcers on his left arm after two years of treatment (Figure 1).
No other symptoms such as fever or weight loss were reported. The physical examination revealed no mucous lesions or hepatosplenomegaly. The blood count, electrolytes, liver and kidney function tests were normal. The leishmanin skin test was positive (19×9 mm) and parasite culture in Novy-Mac Neal-Nicolle (NNN) medium was positive for Leishmania. Indirect immunofluorescence was negative. Leishmania (Leishmania) infantum was identified by PCR-RFLP from the patient’s skin biopsy sample, which was confirmed by direct sequencing of the PCR product. HIV serology was negative. Histopathological examination showed lymphohistiocytic infiltrate with granulomas (Figure 2).
The patient was treated with N-methyl-glucamine (20 mgSbV/kg/day) for 20 days with interruption of adalimumab and methotrexate during therapy (Figure 3). Although the treatment was discontinued for a week, due to elevation of transaminases (TGO 48 U/L and TGP 62 U/L) the lesions presented clinical cure after the end of therapy.
Discussion
In the Northern region of Brazil more than 90% of the Cutaneous Leishmaniasis (CL) are caused by Leishmania (Viannia) guyanensis and in other regions 80% by Leishmania (Viannia) braziliensis and 20% by Leishmania (Leishmania) amazonensis [1,2]. The patient is from the northern region of the state of Minas Gerais where Leishmania (Viannia) braziliensis is the main causative agent of CL and it is also an endemic area of visceral leishmaniasis (VL) caused by Leishmania (Leishmania) infantum. In the Americas Leishmania (Leishmania) infantum also known as Leishmania (Leishmania) chagasi is the most commonly species involved in cases of VL and has been occasionally associated with manifestations of CL. These cases are classified as post-kala-azar dermal leishmaniasis that usually occurs after treatment of VL as non-ulcerated papular lesions all over the skin, and rarely as the first manifestation of VL. To date no Brazilian cases of isolated cutaneous lesions caused by viscerotropic Leishmania species had been reported.
The fact that Leishmania (Leishmania) infantum may cause isolated CL suggests that immune response is crucial to determine the course of infection [3]. Studies have demonstrated that viscerotropic species in Honduras and the Mediterranean region showed low sensitivity to the action of complement, high infectivity and survival in macrophages when compared to dermotrophic strains [4]. The size of the inoculum and the inoculation route also appear to be important in the clinical spectrum of the disease [4]. High levels of intravenously inoculum were associated with visceralization by Leishmania (Leishmania) infantum strains in BALB/c mice genetically susceptible [4].
The use of anti-TNF alpha to treat cutaneous disorders such as psoriasis has become increasingly common. The aim of this strategy is to reduce cutaneous immunologic response and heal inflammatory lesions. This kind of therapy is associated with opportunistic infections especially those where granuloma formation plays an important role in the host defense, such as cutaneous tuberculosis and leishmaniasis [4]. Cases reported in Spain of patients treated with adalimumab who developed CL and studies on the immunopathogenesis of the disease suggest that the formation of granulomas in these patients may be related to the induction of Th17 immune response and activation of Toll-like receptor-9 (TLR9) by Leishmania [5].
Despite theTh1 response is classically associated with protection against Leishmania recent studies showed that the production of cytokines related to Th17 lymphocyte activation also appears to be protective [6-8]. The Th17 cells are CD4+ T lymphocytes that produce pro-inflammatory IL-17 primarily by inducing the expression of several inflammatory mediators, and recruitment of neutrophils [9]. Experimental models have shown that a pro-inflammatory action is related to defence against a variety of infectious diseases [7,10,11]. Dendritic cell sand macrophages are capable of responding to IL-17 stimulation with increased production of IL-12, IFN-gamma and nitric oxide, leading to killing of intracellular pathogens [12].
Several aspects of the initial steps of the immune response after Leishmania infection are unknown. The signaling pathway of Toll-like receptors (TLRs) is one of the first systems of defense against Leishmania [13,14]. After the recognition of specific pathogen associated molecular patterns (PAMPs), TLRs trigger the NF-B releasing which passes into the nucleus and promotes the transcription and synthesis of pro-inflammatory cytokines [13,14].
Recently, TLR9 has been described in a higher proportion in the granulomas produced by Leishmania (Viannia) braziliensis and it was concluded that TLR9 is important to develop and maintain the granulomas [5,13]. It is likely that Leishmania DNA fragments can bind to TLR9 in macrophages and dendritic cells, activating them and acting, as described in mycobacteria, causing pulmonary granulomatous response in rat models [5]. TLR9 could regulate Th17 activation and increase the secretion of IL-17A promoting the formation and maintenance of granulomas mediated by neutrophils [5].
We described a case of CL without visceral manifestation caused by Leishmania (Leishmania) infantum with formation of granulomas in a patient using anti-TNF alpha and methotrexate, both immunosuppressive drugs. In this case, the absence of visceralization could be explained by the presence of cellular immunity demonstrated by the positivity of leishmanin skin test, the granulomatous infiltrate in the histopathological examination and adequate response to the treatment [15]. Cases of CL worsened or triggered during the use of corticosteroids and immunosuppressive drugs such as methotrexate are frequent, however, in the present case the biological therapy may have been the main factor triggering the disease, since it is clearly associated with an increased risk of infections. We strongly believe that this patient was carrying on an unapparent infection by Leishmania (Leishmania) infantum and that anti-TNF alpha had been the trigger for the clinical manifestation of the disease.
To our knowledge this is the first report of human CL caused by Leishmania (Leishmania) infantum without visceral manifestation in Brazil, with only preceding canine VL-associated CL and atypical cases of CL by viscerotropic species [16].
Conclusion
Leishmania infection in patients treated with anti-TNF alpha has to be remembered as an opportunistic disease associated with biological therapies, especially in endemic countries. The role of anti-TNF alpha to CL by viscerotropic species is unclear.
References
  1. Name RQ, Borges KT, Nogueira LSC, Sampaio JHD, Tauil PL, et al. (2005) Clinical, epidemiological and therapeuthic study of 402 patients with American cutaneous leishmaniasis seen at University Hospital of Brasilia, DF, Brazil. An Bras Dermatol 80: 249-254

  2. Department of Epidemiological Surveillance (2007) Manual for the Surveillance of American Cutaneous Leishmaniasis/ Ministry of Health. Secretariat of Health Surveillance. Department of Epidemiological Surveillance. (2nd Edn), Publishing House of the Ministry of Health, Brazil.

  3. Belli A, García D, Palacios X, Rodriguez B, Valle S, et al. (1999) Widespread atypical cutaneous Leishmaniasis caused by Leishmania (L.) Chagasi in Nicaragua. Am J Trop Med Hyg 61: 380-385.

  4. Campos-Ponce M, Ponce C, Ponce E, Maingon RDC (2005) Leishmaniachagasi/infantum: further investigations on Leishmania tropisms in atypical cutaneous and visceral leishmaniasis foci in Central America.ExpParasitol109: 209-219.

  5. Romero-Maté A, Martínez-Sánchez D, Tardío JC, Amalia Moreno-Torres A, García-Donoso C, et al. (2012) Cutaneous leishmaniasis with histopathologic pattern of on necrotizing granulomatous dermatitis in patients treated with adalimumab. Dermatol Online J 18: 7.

  6. Liew FY, Parkinson C, Millott S, Severn A, Carrier M (1990) Tumor Necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunol 69:570-573.

  7. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, et al. (2009) IL-17 and IL-22 are associated with protection against human kalaazar caused by Leishmaniadonovani. Invest 119: 2379-2387.

  8. Novoa R, Bacellar O, Nascimento M, Cardoso TM, Ramasawmy R, et al. (2011) IL-17 and Regulatory Cytokines (IL-10 and IL-27) in L. braziliensis Infection. Parasite Immunol 33: 132-136.

  9. Kumar R, Nylén S (2012) Immunobiology of visceral leishmaniasis. Front Immunol 3: 251.

  10. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, et al. (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206: 299-311.

  11. da MattaGuedes PM, Gutierrez FR, Maia FL, Milanezi CM, Silva GK, et al. (2010) IL-17 produced during Trypanosomacruzi infection plays a central role in regulating parasite-induced myocarditis. PLoSNegl Trop Dis 4: e604.

  12. Cunha FQ, Assreuy J, Xu D, Charles I, Liew FY, et al. (1993) Repeated induction of nitric oxide synthase and leishmanicidal activity in murine macrophages. Eur J Immunol 23: 1385-1388.

  13. Tuon FF, Fernandes ER, Pagliari C, Duarte MI, Amato VS (2010) The expression of TLR9 in human cutaneous leishmaniasisis associated with granuloma. Parasite Immunol 32: 769-772.

  14. Tuon FF, Amato VS, Bacha HA, Almusawi T, Duarte MI, et al. (2008) Toll-like receptors and leishmaniasis. Infect Immun 76: 866-872.

  15. Wilson ME, Jeronimo SM, Pearson RD (2005) Immunopathogenesis of infection with the visceralizingLeishmania species. MicrobPathog 38: 147-160.

  16. Cavalcanti A, Lobo R, Elisa Cupolillo E, Bustamante F, Porrozzi R (2012) Canine cutaneous leishmaniasis caused by neotropicalLeishmaniainfantum despite of systemic disease: a case report. ParasitolInt 61: 738-740.

Figures at a glance

image image image
Figure 1 Figure 2 Figure 3
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11594
  • [From(publication date):
    November-2014 - Jun 28, 2017]
  • Breakdown by view type
  • HTML page views : 7826
  • PDF downloads :3768
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords